Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N A Risebrough

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Coverage With Evidence Development Activities Around The World: An Environment ScanC M Li, N A Risebrough, M Hux
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 16, 2002
Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble techniqueV S Naraine, N A Risebrough, P Oh, et al.
Respiratory Research|January 30, 2019
Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspectiveM T Driessen, J Whalen, B Seewoodharry Buguth, et al.
Respiratory Research|November 22, 2018
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspectiveM T Driessen, J Whalen, B Seewoodharry Buguth, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Validating A Model To Predict Disease Progression Outcomes In Patients With COPDN A Risebrough, A Briggs, T M Baker, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Coverage With Evidence Development Activities Around The World: An Environment ScanC M Li, N A Risebrough, M Hux
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 16, 2002
Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble techniqueV S Naraine, N A Risebrough, P Oh, et al.
Respiratory Research|January 30, 2019
Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspectiveM T Driessen, J Whalen, B Seewoodharry Buguth, et al.
Respiratory Research|November 22, 2018
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspectiveM T Driessen, J Whalen, B Seewoodharry Buguth, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Validating A Model To Predict Disease Progression Outcomes In Patients With COPDN A Risebrough, A Briggs, T M Baker, et al.
Pageof 1